Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusionEric Kauffman, Ramaprasad Srinivasan|BMC Cancer|2019Cited by 30
A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell CarcinomaJohn A. Ligon, John Glod, Karel Pacák et al.|Clinical Cancer Research|2022Cited by 22
Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell CarcinomaRoma Pahwa, Ramaprasad Srinivasan|Journal of Experimental & Clinical Cancer Research|2022Cited by 12
Data from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell CarcinomaJohn A. Ligon, John Glod, R. Taylor Sundby et al.|Unknown|2023Cited by 0
Data from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell CarcinomaJohn A. Ligon, John Glod, R. Taylor Sundby et al.|Unknown|2023Cited by 0